Heterogeneity of protein kinase C β2 expression in lymphoid malignancies

Histopathology

Volumn 50, Issue 5, 2007, Pages 561-566

  Decouvelaere, A V ^a   Morschhauser, F ^b   Buob, D ^b   Copin, M C ^b   Dumontet, C ^c  

^a CENTRE LÉON BÉRARD   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

Immunohistochemistry; NHL; PKC

Indexed keywords

PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ARTICLE; CELL HETEROGENEITY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHOOL CHILD; T CELL LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROTEIN KINASE C; TUMOR MARKERS, BIOLOGICAL;

EID: 33947615116     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02666.x     Document Type: Article

References (14)

1. Carter CA. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr. Drug Targets 2000; 1; 163-183.
2. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 2002; 8; 68-74.
3. Hans CP, Weisenburger DD, Greiner TC et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. 2005; 18; 1377-1384.
4. Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2001.
5. Leitges M, Schmedt C, Guinamard R et al. Immunodeficiency in protein kinase Cbeta-deficient mice. Science 1996; 273; 788-791.
6. King LB, Norvell A, Monroe JG. Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. J. Immunol. 1999; 162; 2655-2662.
7. Su TT, Guo B, Kawakami Y et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat. Immunol. 2002; 3; 780-786.
8. Venkataraman C, Chen XC, Na S et al. Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking. Immunol. Lett. 2006; 20; 20.
9. Felli MP, Vacca A, Calce A et al. PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 2005; 24; 992-1000.
10. Lahn M, Sundell K, Kohler G. The role of protein kinase C-alpha in hematologic malignancies. Acta Haematol. 2006; 115; 1-8.
11. Kamimura K, Hojo H, Abe M. Characterization of expression of protein kinase C isozymes in human B-cell lymphoma. Relationship between its expression and prognosis. Pathol. Int. 2004; 54; 224-230.
12. Virchis A, Ganeshaguru K, Hart S et al. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol. J. 2002; 3; 131-136.
13. Teicher BA, Menon K, Alvarez E et al. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo 2001; 15; 185-193.
14. Rieken M, Weigert O, Pastore A et al. Inhibition of protein kinase C beta by enzastaurin (LY 317615) induces alterations of key regulators of cell cycle and apoptosis in mantle cell lymphoma and synergizes with chemotherapeutic agents in a sequence dependent manner. San Diego: American Society of Hematology 2005; 2416.